Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug.

Snigdha SamarpitaJoo Young KimMahaboob Khan RasoolKyoung Soo Kim

Published in: Arthritis research & therapy (2020)

Based on the drug repositioning concept, TAK-242, which is used for the treatment of TLR4-mediated inflammatory diseases, shows potential for cost-effective development as a remedy for rheumatoid arthritis or to control the progression of RA.

Keyphrases

toll like receptor
rheumatoid arthritis
inflammatory response
nuclear factor
disease activity
immune response
ankylosing spondylitis
interstitial lung disease
oxidative stress
adverse drug
human health
combination therapy
drug induced
risk assessment
smoking cessation
replacement therapy
electronic health record